Biomarker discovery

Koneksa Enrolls First Patient in LEARNS Observational Study to Remotely Measure Disease Progression Using Digital Biomarkers in Neurodegenerative Disorders

Retrieved on: 
Tuesday, February 20, 2024

The remote measurement of disease utilizing digital biomarkers provides an opportunity to capture disease change and impacts in the context of daily living and in a more convenient fashion.

Key Points: 
  • The remote measurement of disease utilizing digital biomarkers provides an opportunity to capture disease change and impacts in the context of daily living and in a more convenient fashion.
  • The remote measurement of disease utilizing digital biomarkers provides an opportunity to capture disease change and impacts in the context of daily living and in a more convenient fashion.
  • The study will enroll up to 70 participants with Parkinson’s disease for the disease progression portion of the study.
  • The LEARNS study represents an effort utilizing digital biomarkers to remotely measure disease progression, providing a patient-centered opportunity to capture disease changes and impacts in the context of daily living.

Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology

Retrieved on: 
Wednesday, January 31, 2024

Infinity Bio , Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly ( MIPSA ) technology.

Key Points: 
  • Infinity Bio , Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly ( MIPSA ) technology.
  • Infinity Bio's proprietary MIPSA technology is a leap forward in antibody profiling.
  • This capability places Infinity Bio at the forefront of disease research, biomarker discovery, monoclonal antibody optimization, vaccine development, and therapeutic advancement.
  • H. Benjamin Larman, Ph.D., co-founder and CSO of Infinity Bio and Associate Professor of Pathology at Johns Hopkins School of Medicine, explains, “Infinity Bio was formed to elucidate each individual’s portfolio of antibodies.

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Retrieved on: 
Thursday, January 25, 2024

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderID framework to develop predictive biomarkers for DDR-directed therapies.

Key Points: 
  • The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderID framework to develop predictive biomarkers for DDR-directed therapies.
  • “Debiopharm continues to lead the oncology field in adopting artificial intelligence solutions at various stages across our preclinical and clinical development programs.
  • “Genialis’ RNA biomarkers have proved especially well-suited to support the development of new drugs targeting complex biological systems,” said Mark Uhlik, Vice President of Biomarker Discovery at Genialis.
  • Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Retrieved on: 
Thursday, January 25, 2024

The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderIDTM framework to develop predictive biomarkers for DDR-directed therapies.

Key Points: 
  • The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderIDTM framework to develop predictive biomarkers for DDR-directed therapies.
  • “Debiopharm continues to lead the oncology field in adopting artificial intelligence solutions at various stages across our preclinical and clinical development programs.
  • “Genialis’ RNA biomarkers have proved especially well-suited to support the development of new drugs targeting complex biological systems,” said Mark Uhlik, Vice President of Biomarker Discovery at Genialis.
  • Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.

Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones

Retrieved on: 
Wednesday, January 10, 2024

This strategic alliance leverages the unique capabilities of TNL’s AI Digital Cells Lab platform and Debiopharm’s deep pharmaceutical expertise to bring cancer drugs into new frontiers of innovation.

Key Points: 
  • This strategic alliance leverages the unique capabilities of TNL’s AI Digital Cells Lab platform and Debiopharm’s deep pharmaceutical expertise to bring cancer drugs into new frontiers of innovation.
  • 2) Drugs’ Combination Identification: Utilizing TNL’s AI digital knockdowns, it will identify valuable combinations with other drugs in development, enhancing the therapeutic potential of Debiopharm's cancer drug.
  • 3) Mechanism of Action Validation: TNL’s mechanistic digital cell clones will be instrumental in validating the mechanism of action of Debiopharm's cancer drug, ensuring a deep understanding of its efficacy.
  • 4) Drugs’ Comparison: TNL’s digital cell clones will provide comparative analysis, allowing Debiopharm to assess its cancer drug against other existing cancer treatments.

Genialis Presents Data at SITC 2023 on RNA-Based Biomarkers to Predict Immunotherapy Response

Retrieved on: 
Friday, November 3, 2023

Genialis , the RNA-biomarker company, today announced new data detailing how RNA sequencing data can help elucidate tumor biologies that may be amenable to immunotherapies and targeted agents.

Key Points: 
  • Genialis , the RNA-biomarker company, today announced new data detailing how RNA sequencing data can help elucidate tumor biologies that may be amenable to immunotherapies and targeted agents.
  • The information was presented in two posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting .
  • “RNA biomarkers provide more comprehensive and dynamic insights into cellular states and regulatory processes compared with DNA or protein biomarkers.
  • For more information on ResponderID or to make an appointment with Genialis to learn more, please visit www.genialis.com

Exosomes Market Set for Substantial Growth, Forecasted to Exceed US$ 1,955.3 Million with a CAGR of 31.3% by 2032

Retrieved on: 
Thursday, May 18, 2023

COVINA, Calif., May 18, 2023 /PRNewswire/ -- What is Exosomes Market?

Key Points: 
  • They can transfer bioactive molecules, such as proteins, nucleic acids, and growth factors, to target cells, stimulating their healing and regenerative properties.
  • Targeted Drug Delivery: Exosomes can be engineered to carry therapeutic cargo, such as drugs or genetic material, to specific target cells or tissues.
  • Non-Immunogenicity: Exosomes derived from the patient's own cells (autologous) are considered non-immunogenic, reducing the risk of immune rejection or adverse reactions.
  • Liquid biopsy-based detection and analysis of exosomes have the potential to revolutionize cancer diagnosis, monitoring treatment response, and detecting other diseases.

Genomics Market to Reach $94.86 Billion by 2030 at CAGR 16.5%: Grand View Research, Inc.

Retrieved on: 
Wednesday, April 19, 2023

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to register a CAGR of 16.5% in the forecast period owing to the increasing demand for novel therapeutic and research applications in genomics.
  • Read full market research report more latest industry insights, " Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), By Deliverables, End-use, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global genomics market on the basis of application, deliverables, end-use, and region
    Genomics Market - Application & Technology Outlook (Revenue, USD Million, 2018 - 2030)

European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

Retrieved on: 
Monday, March 27, 2023

The HYFT Technology serves as the core of the BioStrand’s LENSai Integrated TechnologyTM platform which provides cutting-edge data solutions and antibody discovery.

Key Points: 
  • The HYFT Technology serves as the core of the BioStrand’s LENSai Integrated TechnologyTM platform which provides cutting-edge data solutions and antibody discovery.
  • The patent will provide BioStrand’s LENSai Integrated Technology with broad protection, further strengthening the Company’s patent portfolio position and enabling exclusive access to the HYFT Technology.
  • The Company anticipates favorable outcomes in other countries as well, as many patent offices worldwide consider the status of related European cases to be highly relevant to the decision to grant patents.
  • Another application of HYFT-based technologies is tied to NLP, which involves analyzing and extracting information from written or spoken language.

Global Cancer/Tumor Profiling Market Report 2022: Technological Advancements in Cancer Profiling Techniques Boosting Sector

Retrieved on: 
Friday, December 2, 2022

The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period.

Key Points: 
  • The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period.
  • Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies.
  • Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers.
  • Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers.